RxDoctor Payments DataLook up a doctor →

Mikhail Shtivelband, MD

Hematology & Oncology · Chandler, AZNPI 1740254473

Payments from drug & device makers

$9,143,787in general payments, 2019–2025

Across 1,182 payments — averaging $7735.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$5.1M
  • AstraZeneca$1.5M
  • Merck$975K
  • Boehringer Ingelheim$550K
  • Astrazeneca UK Limited$330K
  • Daiichi Sankyo Inc.$266K
  • plus $430K from 54 others
$6,217in research payments, 2019–2025

Across 4 payments — averaging $1554.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$3K
  • F. Hoffmann-la Roche AG$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis120$5,059,950
AstraZeneca(2 entities)59$1,531,931
Merck135$975,167
Boehringer Ingelheim6$549,687
Astrazeneca UK Limited13$330,321
Daiichi Sankyo Inc.108$266,417
Bayer72$123,653
Eli Lilly8$73,106
F. Hoffmann-la Roche AG21$71,354
Morphosys AG2$40,655
Bristol Myers Squibb56$26,151
TG Therapeutics, Inc.16$25,589
Genentech, Inc.3$18,747
Pfizer70$15,694
EMD Serono, Inc.9$12,615
E.r. Squibb & Sons, L.L.C.32$10,203
Boehringer Ingelheim International GmbH11$2,655
Tesaro, Inc.9$2,044
Johnson & Johnson101$1,432
Astellas Pharma US Inc23$628
Amgen30$542
Pharmacyclics LLC, An Abbvie Company27$451
AbbVie19$373
Genentech USA, Inc.18$312
Sanofi18$291
Puma Biotechnology, Inc.14$252
Incyte Corporation16$250
Seagen Inc.15$229
GSK10$207
Novocure GmbH1$200
Takeda Pharmaceuticals U.S.A., Inc.9$200
Gilead(2 entities)10$184
Athenex Pharmaceutical Division, LLC1$175
Rigel Pharmaceuticals, Inc.10$171
Regeneron Healthcare Solutions, Inc.8$167
Array Biopharma Inc10$155
Ipsen Biopharmaceuticals, Inc10$151
Sun Pharmaceutical Industries Inc.8$134
Eisai Inc.6$112
Blueprint Medicines Corporation7$111
Jazz Pharmaceuticals Inc.5$105
Karyopharm Therapeutics Inc.5$75
Mirati Therapeutics, Inc.3$75
Stemline Therapeutics Inc.3$59
Dova Pharmaceuticals3$52
Taiho Oncology, Inc.3$52
G1 Therapeutics, Inc.3$51
Kyowa Kirin, Inc.3$49
Lilly USA, LLC3$47
AVEO Pharmaceuticals, Inc.3$47
Lexicon Pharmaceuticals, Inc.2$41
AMAG Pharmaceuticals, Inc.2$40
Myovant Sciences Inc.2$38
Dendreon Pharmaceuticals LLC2$36
Exelixis Inc.2$32
Geron Corporation1$31
Springworks Therapeutics, Inc.1$30
Beigene USA, Inc.1$24
Epizyme, Inc.1$23
Servier Pharmaceuticals LLC1$23

How this compares

$9,143,787 in reported general payments places this provider in the 95th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona →

Medicare billing

Part B allowed, 2024
$4,126,188
Medicare patients
541
Services billed
215,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Chandler

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →